Human herpesvirus 6 (HHV-6) infection is common after transplantation; HHV-6 is known to interact with other viruses and induce immunosuppression. Whether HHV-6 plays a role in the occurrence of cytomegalovirus (CMV) infection after transplantation was investigated. In a cohort of 247 liver transplant recipients, HHV-6 seroconversion was identified as a significant risk factor for development of symptomatic CMV infection (P õ .001), including CMV organ involvement (P õ .001), even in the presence of the other significant risk factors: D / /R 0 CMV serologic status (P õ .001) or use of OKT3 after transplantation (P Å .002). Subgroup analysis indicated that HHV-6 seroconversion was significantly associated with symptomatic CMV infection in the D / /R / but not in the D / /R 0 CMV serologic group (P õ .001 and P Å .11, respectively). These results indicate that HHV-6 seroconversion is a marker for CMV disease after transplantation and suggest that additional studies using more sensitive diagnostic techniques are warranted to determine the relationship between HHV-6 and CMV infection after transplantation.
Human herpesvirus 6 (HHV-6) is a cytopathic lymphotropic [13, 14] , as well as an association with increased graft rejection [9, 12] . In addition, an interrelationship between CMV and virus with characteristic biologic effects, antigenic features, and endonuclease restriction patterns that distinguish it from HHV-6 infection has been suggested by an increased frequency of rising IgG titers to HHV-6 following CMV infection [15] . other members of the herpesvirus family [1] . In vitro, cell tropism is most marked for T lymphocytes but has also been After orthotopic liver transplantation, CMV is a frequent infectious complication leading to significant morbidity and noted for B lymphocytes, monocytes, macrophages, glial cells, and fibroblasts [2] . Seroprevalence is almost universal at 2 mortality [16] . Prophylaxis and preemptive treatment with antiviral agents are two strategies aimed at reducing CMV infection years of age, and antibody is detected in 85% -100% of adults [3] . Primary infection with HHV-6 causes exanthem subitum [17] and require the identification of epidemiologic, clinical, or laboratory markers identifying the transplant recipient at (roseola infantum) in infants [4] , while in older children and adults, infection may produce an infectious mononucleosisincreased risk of the development of symptomatic CMV infection. The epidemiologic risk factors thought to influence the like syndrome [5] . HHV-6 infection of peripheral blood mononuclear cells is marked by immunosuppression, with reduced shift from asymptomatic to symptomatic CMV infection after solid organ transplantation include belonging to the donorcellular proliferation and interleukin-2 synthesis [6] . In addition, coinfections with both HHV-6 and other viruses, espepositive/recipient-negative (D / /R 0 ) CMV serologic status, as well as the use of OKT3, especially in the D / /R / CMV serocially cytomegalovirus (CMV), are described, particularly in cases of pneumonitis after bone marrow transplantation [7] .
group [18, 19] . However, in this latter group, additional unidentified risk factors appear to be present to account for symptomLike other members of the herpesvirus family, HHV-6 may be cultured or cause clinical syndromes in immunocompromised atic CMV infection. On the basis of special features of HHV-6 outlined above hosts, including transplant recipients [8, 9] . While the estimated rate of detection of HHV-6 following organ transplantation and the fact that HHV-6 infection temporarily precedes symptomatic CMV infection after solid organ transplantation [20, ranges between 14% and 82% in different types of transplant recipients [10 -12] , its clinical impact after organ transplanta-21], we have investigated whether evidence of HHV-6 infection detected by serology is a significant risk factor for the develoption is unclear. Febrile illness with cutaneous rash, fulminant hepatitis, and interstitial pneumonitis have all been described ment of symptomatic CMV infection after liver transplantation. Using a time-dependent multivariate analysis, we evaluated whether the serologic response to HHV-6 3 months after orthotopic liver transplantation was a risk factor for symptomatic CMV infection in a cohort of 247 transplant recipients. JID 1997; 176 (November) tion within the first 90 days were analyzed up to the time of samples for CMV cultures were prospectively collected at weekly intervals for the first 2 months and at 3 months after transplantation. retransplantation only. Mean age at the time of transplantation was 47.5 years, and 50.2% were men. Etiologies leading to liver In addition, fluid or tissue specimens were obtained to detect CMV whenever CMV infection was clinically suspected. CMV IgG titers transplantation were primary sclerosing cholangitis (68 patients), primary biliary cirrhosis (47), hepatitis C (18), hepatitis B (10), a 1 -were determined by anti-complement immunofluorescence and IgM titers by indirect immunofluorescence. antitrypsin deficiency (9) , alcoholic liver disease (24), cryptogenic cirrhosis (25) , autoimmune chronic active hepatitis (7), fulminant CMV infection was defined as the isolation of CMV from any body fluid. CMV infection was deemed asymptomatic if infection hepatic failure (9), tumors (10) , and miscellaneous causes (20 hypoxia, and lack of other microbial pathogens) or gastrointestinal received CMV-seronegative blood products (for at least the initial 24 units). During the period in which these patients were transdisease, including CMV hepatitis. Those definitions have been previously described [25] . planted, 117 patients entered into a study comparing two regimens of CMV prophylaxis. Fifty-five patients received intravenous ganStatistics. The risk of symptomatic CMV infection and CMV with organ involvement in the first 90 days after transplantation ciclovir (5 mg/kg twice a day) for 2 weeks followed by oral acyclovir (800 mg four times a day) for 14 weeks, and 62 received was estimated by use of the Kaplan-Meier method [26] . The relationship between the end points of symptomatic CMV infection oral acyclovir (800 mg four times a day) for 16 weeks.
Immunosuppressive drug regimens consisted of prednisone in and of CMV with organ involvement with HHV-6 infection and with known risk factors for the development of CMV infectioncombination with cyclosporin and azathioprine or FK506, as previously described [22] . Biopsy-proven cellular rejection episodes D/R CMV serostatus, fulminant hepatic failure before transplantation, pretransplant prothrombin time in the upper quartile, total were treated with intravenous methylprednisolone followed by OKT3 administration in the steroid-resistant cases as previously units of red blood cells transfused in the upper quartile, total units of platelets transfused intraoperatively in the upper quartile, total described [19] .
HHV-6 antibody determination. Frozen (070ЊC) stored serum units of fresh frozen plasma transfused intraoperatively in the upper quartile, and total of cryoprecipitate transfused intraoperatively obtained before transplantation and at 3 months after transplantation (mean, 98.7 days; median, 90) was analyzed for IgM and IgG in the upper quartile [27] -were compared in a univariate analysis using the log rank test. In addition, the following postoperative anti-HHV-6 antibodies by an indirect immunofluorescence assay [1] . Samples with high levels of polyclonal immunoglobulin were CMV risk factors were analyzed by time-dependent Cox modeling: OKT3 use postoperatively, hepatic artery thrombosis, and vanpretreated with Zorba solution (Zeus Scientific, Raritan, NJ) to remove nonspecific IgG. Briefly, test slides containing cord blood ishing bile duct syndrome. In addition, the Cox model was used to assess HHV-6 status by multivariate analysis while adjusting mononuclear cells infected with HHV-6 subgroup B, strain Z-29 (Bion Enterprises, Park Ridge, IL) were reacted with different one at a time for the other risk factors, namely D / /R 0 CMV serostatus and OKT3 use, previously found to be significantly dilutions of the patient sera; specific antibodies were detected with fluorescent tagged anti-human IgM or IgG and read using a fluoassociated with symptomatic CMV infection and CMV with organ involvement [28] . To assess the relationship between HHV-6 seroconversion and CMV events after transplantation, we determined the probability of symptomatic CMV infection or CMV with organ involvement in the first 90 days after transplantation for each category of HHV-6 infection after transplantation: primary, secondary, or none. The results are depicted in the plots of the 90-day probability of symptomatic CMV infection or CMV with organ involvement for each HHV-6 group ( figures 1 and 2) .
The percentage of patients with symptomatic CMV infection or CMV organ involvement was significantly higher in patients who seroconverted to HHV-6 after transplantation than in those who did not (P õ .001 for symptomatic CMV infection and P õ .001 for CMV organ involvement) (table 2). No significant difference was observed between primary or secondary HHV-6 seroconversion. A trend between HHV-6 seronegativity before /R / subgroup, in which the presence of the aboveidentified risk factors is insufficient to fully predict the risk of symptomatic CMV infection after transplantation.
Our data suggest that HHV-6 infection is a risk factor predisposing the patient to severe CMV infection; however, this is only implied from the use of serologic markers. Because serology is a suboptimal diagnostic method for the detection of herpesvirus infections in transplant recipients, results from this study suggest the need to study in further detail whether such findings are confirmed when more sensitive techniques (shell establish whether the association between HHV-6 seroconversion and CMV disease is due to HHV-6 infection or whether the seroconversion to HHV-6 is a marker of a particular state .001), but the difference between those with and without HHVof immunologic status that predisposes to more severe CMV 6 seroconversion was not statistically significant in the CMV infection. D / /R 0 serologic subgroup (61% vs. 40%, P Å .11).
It is possible that HHV-6 seroconversion may be a better Univariate and multivariate analysis. To confirm the prognostic marker than more sensitive diagnostic techniques. above results and determine whether HHV-6 seroconversion is For example, HHV-6 seroconversion could have been genera risk factor for symptomatic CMV infection after transplantaated in response to a specific HHV-6 strain or to a high virus tion, a univariate analysis was performed. Of all of the variables load present in tissues or body compartments, not detected by studied in the univariate analysis (see Methods), only the CMV applying sensitive diagnostic techniques to peripheral blood D / /R 0 serologic subgroups (relative risk [RR], 3.4; 95% consamples. Alternatively, a genuine cross-reaction with a specific fidence interval [CI], 1.6 -7.7; P Å .0001), OKT3 use (RR, CMV protein that is not detected by conventional CMV sero-3.3; CI, 1.6 -7.7; P Å .0019), and HHV-6 seroconversion (RR, logic techniques may be present. If this were the case, the 4.0; CI, 2.3 -8.0; P Å .0001) were associated with an increased presence of these antibodies detected as anti -HHV-6 antibodrisk of symptomatic CMV infection. By use of a pairwise ies would be a marker of an immune response with an important multiple regression analysis, we determined that, as shown in role in CMV pathogenesis leading to invasive infection. Last, table 4, HHV-6 seroconversion was a significant risk factor and through an initial evaluation (table 1) , we have excluded even in the presence of either the D / /R 0 subgroup or OKT3 cross-reactivity between CMV and HHV-6 antibodies that use.
could have been present due to the homology between the gB of both viruses [29, 30] . Also, unlike acute Epstein-Barr virus infection, during which IgG antibody responses to other viruses Discussion occur with associated rises to both latent (herpesviruses) and nonlatent viruses (measles virus), the rises seen to both HHVThis study indicates that HHV-6 seroconversion after liver 6 and CMV appear to occur in the absence of associated antitransplantation is a marker of increased risk of symptomatic CMV infection in the first 90 days after transplantation, indebody rises [15, 29] . Table 2 . CMV outcomes with respect to HHV-6 serostatus after transplantation, number of events (%), and probability of 90-day survival free of CMV event.
Probability of 90-day CMV infection Probability of 90-day CMV symptomatic survival free of with organ survival free of infection symptomatic involvement infection with organ HHV-6 serostatus (n Å 50) infection (n Å 30) involvement Our understanding of the mechanisms of potential HHV-6 Our data show that patients are often seronegative for both interaction with CMV is hindered by the limited data on HHV-CMV and HHV-6 before transplant, and these persons develop 6 infection following orthotopic liver transplantation. Support severe primary CMV infections associated with primary HHVfor the concept of specific interactions between HHV-6 and 6 infections. Infection with HHV-6 after transplantation may CMV and their direct or indirect impact exist [13, 19] . HHVmodify the course of CMV reactivation and make symptomatic 6 infection is associated with more severe clinical symptoms infection, especially with organ involvement, more likely. Risk if concomitant CMV infection is present [21] , and serologically factors for HHV-6 infection after transplantation are based on proven CMV infections are described in association with HHVanecdotal reports. A liver transplant recipient seronegative for 6 reactivations in solid organ transplant recipients [15] . Dual HHV-6 before transplant developed HHV-6 infection after reserologic responses to both HHV-6 and CMV are also deceiving a seropositive donor liver, while a renal transplant scribed in immunocompetent persons [5, 29] . HHV-6 is a recipient developed HHV-6 infection after OKT3 use [33, 34] . lymphotropic virus with particular tropism for the CD4 T lymAs these risk factors are similar to those for CMV infection, phocyte, resulting in immunosuppression [6] . The recent findcoinfection may be facilitated. ing that CMV gH and gL glycoproteins can form heterologous Transfused blood products are a potential mechanism by complexes with HHV-6 gH and gL glycoproteins raises a possiwhich herpesviruses such as CMV may be transmitted after ble mechanism of interaction during cell coinfection [31] . The transplantation [35] . The same may be true of HHV-6. Allogetiming of HHV-6 infection at 2 -4 weeks after transplant and neic bone marrow transplant and orthotopic liver transplant before CMV infection occurs (6 -12 weeks after transplant) recipients are both susceptible to HHV-6 infection after transwould allow for interaction to occur [20, 21] . Alternatively, plantation, and both transplant groups require large volumes there may not be a direct interaction. HHV-6 seroconversion of blood products [21, 36, 37] . Intravenous immunoglobulin may be a marker of infection with as-yet-unidentified herpesvitransfusions may be a mechanism for passive transfer of immurus, which may interact with CMV and whose antibodies might noglobulin, giving rise to false-positive serologic results for be cross-reactive with those of HHV-6. The mechanism may HHV-6 IgG, as has been suggested in the case of allogeneic also involve HHV-7, as it has been shown that HHV-7 infection bone marrow transplant recipients [36] . The transfusion of after renal transplantation is a risk factor for symptomatic CMV blood products could also in theory lead to the passive transfuinfection [32] .
sion of HHV-6 IgG. However, liver transplant recipients receive the majority of their transfusions intraoperatively, and transfused antibodies are unlikely to be detected 90 days later. 
